Company

Myeloid Therapeutics, Inc.

Myeloid Therapeutics develops mRNA-based immunotherapies that target myeloid cells to treat cancer.

About

Myeloid Therapeutics develops mRNA-based immunotherapies designed to engineer and activate myeloid cells in solid tumors. Founded in 2019, the biotechnology company is based in Cambridge, US, and is led by CEO Daniel Getts. In May 2023, it raised USD 73.00 mn in Series A funding led by Hatteras Venture Partners, with participation from 8VC and ARCH Venture Partners.

2Funding rounds

6Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in